Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979216 | 0.89 | PTGDR2 (0.54) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL14979186 | 0.88 | PTGDR2 (0.54) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL16085966 | 0.86 | PTGDR2 (0.59) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL14979252 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL16085905 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL14979245 | 0.83 | PTGDR2 (0.51) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL14979229 | 0.82 | RAB9A (0.48) | ALDH1A1MAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL16104144 | 0.82 | ALDH1A1 (0.61) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL14979241 | 0.78 | PTGDR2 (0.46) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL14979187 | 0.78 | ALDH1A1 (0.64) | ALDH1A1HDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2781508-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP Biosciences Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071880-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | 山东亨利医药科技有限责任公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, NR3C2 | ALDH1A1 3981/4885HDAC3 1571/4885HDAC1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.